Comparison
9q21 13 Microdeletion Syndrome C5681312 vs 6 Phosphogluconate Dehydrogenase Deficiency C5543091
Clinical comparison between 9q21 13 Microdeletion Syndrome and 6 Phosphogluconate Dehydrogenase Deficiency for differential diagnosis and treatment planning.
9q21 13 Microdeletion Syndrome C5681312
A rare chromosomal disorder involving deletion of genetic material from chromosome 9q21. Features vary but may include developmental delays, learning difficulties, and growth differences. Care is supportive and tailored to individual needs.
6 Phosphogluconate Dehydrogenase Deficiency C5543091
A rare enzyme deficiency affecting red blood cells that can cause anemia during oxidative stress. Symptoms may flare with certain medications or infections. Managed with avoidance of triggers.
6 comparison axes
Onset
9q21 13 Microdeletion Syndrome C5681312
0-5
6 Phosphogluconate Dehydrogenase Deficiency C5543091
Variable
Onset patterns differ
Severity
9q21 13 Microdeletion Syndrome C5681312
moderate
6 Phosphogluconate Dehydrogenase Deficiency C5543091
mild
Different severity levels
Chronic
9q21 13 Microdeletion Syndrome C5681312
Chronic
6 Phosphogluconate Dehydrogenase Deficiency C5543091
Chronic
Differing course
Communicable
9q21 13 Microdeletion Syndrome C5681312
No
6 Phosphogluconate Dehydrogenase Deficiency C5543091
No
Different transmission
Body System
9q21 13 Microdeletion Syndrome C5681312
congenital
6 Phosphogluconate Dehydrogenase Deficiency C5543091
metabolic
Same/different system
Category
9q21 13 Microdeletion Syndrome C5681312
genetic
6 Phosphogluconate Dehydrogenase Deficiency C5543091
metabolic
Different category
Bottom line
9q21-13-microdeletion-syndrome-C5681312 and 6-phosphogluconate-dehydrogenase-deficiency-C5543091 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 9q21 13 Microdeletion Syndrome C5681312 | 6 Phosphogluconate Dehydrogenase Deficiency C5543091 | Discriminating power |
|---|---|---|---|
| Developmental delay | May include early developmental delay or learning difficulty; features vary. | Not described as a primary developmental syndrome. | High |
| Anemia with stress | Hemolytic anemia is not a stated core feature. | Anemia may flare with infection or certain medicines. | High |
| Growth difference | Growth differences may occur and need individual assessment. | Growth abnormality is not a described hallmark. | Moderate |
When to favor each condition
Choose 9q21 13 Microdeletion Syndrome C5681312 when
Early developmental or learning concerns
Onset is typically in early childhood and features are congenital.
Moderate
Suspected chromosomal deletion
A genetic test, not an enzyme assay, evaluates this diagnosis.
High
No oxidative-stress anemia pattern
Absence of trigger-related hemolysis makes the metabolic condition less likely.
Moderate
Choose 6 Phosphogluconate Dehydrogenase Deficiency C5543091 when
Anemia after infection or oxidant exposure
This pattern matches the described red-cell enzyme deficiency.
Moderate
Variable age without congenital syndrome
Onset is variable and severity is generally described as mild.
Moderate
Need to assess enzyme activity
Specialist enzyme testing, interpreted clinically, is relevant.
High
How key tests differ
| Test | 9q21 13 Microdeletion Syndrome C5681312 | 6 Phosphogluconate Dehydrogenase Deficiency C5543091 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May show deletion involving 9q21.13. | No chromosomal deletion is expected. | Supports the genetic diagnosis only with clinical correlation. |
| 6-PGD enzyme assay | Not the diagnostic test for this syndrome. | May show reduced enzyme activity if confirmed. | Result must be interpreted by a specialist; no cutoff is supplied. |
| Blood count and hemolysis studies | No specific anemia pattern is established. | Anemia or hemolysis may appear during oxidative stress. | An abnormal result is not itself a diagnosis. |
Prognosis comparison
9q21 13 Microdeletion Syndrome C5681312
- Outcome
- Often a chronic condition with variable developmental and learning needs; exact outcomes are not established.
- Factors
- Feature severity, identified needs, and access to supportive care.
6 Phosphogluconate Dehydrogenase Deficiency C5543091
- Outcome
- Often mild and chronic, with episodes possibly linked to oxidative stress; long-term outcomes are not fully established.
- Factors
- Trigger exposure, infections, and confirmed enzyme status.
Time frame: Both may require long-term follow-up; course differs by individual.
Diagnosis confirmation, comorbidities, and tailored supportive management.
Complications comparison
| Complication | Presentation |
|---|---|
| Learning and development needs | Support needs may be ongoing and variable. Not a characteristic complication. Educational and developmental assessment should be individualized. |
| Hemolytic episode | Not described as typical. May occur with infection or trigger medicines. Avoidance advice requires clinician review of medicines. |
| Growth concern | Possible and should be monitored. Not established as typical. Growth findings need clinical interpretation. |
Patient education highlights
- HighDifferent causes
One is chromosomal and congenital; the other affects a red-cell enzyme. They are not contagious.
- HighWhen to seek care
Report new anemia symptoms, jaundice, or developmental concerns promptly.
- MediumTrigger caution
For the enzyme deficiency, ask a clinician before using new medicines or supplements.